Abstract
Poly(ADP-ribose) polymerases were originally described as DNA repair enzymes. PARP-1, PARP-2 and PARP-3 can be activated by DNA damage and the resulting activation of these enzymes that facilitate DNA repair, seems to be a prerequisite of successful aging. PARP activation helps to maintain genomic integrity through supporting DNA repair systems; however, in parallel these enzymes limit metabolic fitness and make the organism more prone for metabolic diseases. In addition, several other pathways (e.g., proteostasis, nutrient sensing, stem cell proliferation or cellular communication) all contributing to aging, were shown to be PARP mediated. In this review we aim to summarize our current knowledge on the role of PARPs in aging.
Keywords: PARPs, mitochondria, DNA repair, aging, healthspan, energy stress.
Current Protein & Peptide Science
Title:Poly(ADP-Ribose) Polymerases in Aging – Friend or Foe?
Volume: 17 Issue: 7
Author(s): András Vida, Omar Abdul-Rahman, Edit Mikó, Attila Brunyánszki and Peter Bai
Affiliation:
Keywords: PARPs, mitochondria, DNA repair, aging, healthspan, energy stress.
Abstract: Poly(ADP-ribose) polymerases were originally described as DNA repair enzymes. PARP-1, PARP-2 and PARP-3 can be activated by DNA damage and the resulting activation of these enzymes that facilitate DNA repair, seems to be a prerequisite of successful aging. PARP activation helps to maintain genomic integrity through supporting DNA repair systems; however, in parallel these enzymes limit metabolic fitness and make the organism more prone for metabolic diseases. In addition, several other pathways (e.g., proteostasis, nutrient sensing, stem cell proliferation or cellular communication) all contributing to aging, were shown to be PARP mediated. In this review we aim to summarize our current knowledge on the role of PARPs in aging.
Export Options
About this article
Cite this article as:
Vida András, Abdul-Rahman Omar, Mikó Edit, Brunyánszki Attila and Bai Peter, Poly(ADP-Ribose) Polymerases in Aging – Friend or Foe?, Current Protein & Peptide Science 2016; 17 (7) . https://dx.doi.org/10.2174/1389203717666160419144959
DOI https://dx.doi.org/10.2174/1389203717666160419144959 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alteration of the Proline at Position 7 of the HIV-1 Spacer Peptide p1 Suppresses Viral Infectivity in a Strain Dependent Manner
Current HIV Research HIV-1 Vif: HIVs Weapon Against the Cellular Defense Factor APOBEC3G
Current HIV Research Thymidylate Synthase Gene in Pharmacogenetics
Current Pharmacogenomics Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Pharmacogenetics, Target Molecules, and Biological Anti-Rheumatic Drugs in Autoimmune/Chronic Inflammatory Rheumatic Diseases
Current Pharmacogenomics Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Immune Responses to Fungal Infections and Therapeutic Implications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Design of New Oxazaphosphorine Anticancer Drugs
Current Pharmaceutical Design The Regulation of FoxP3-Expressing Regulatory T Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Editorial [Hot Topic: Recombinant Immunotoxins – The Next Generation (Executive Editor: Stefan Barth)]
Current Pharmaceutical Design Emerging Roles of microRNAs in the Molecular Responses to Hypoxia
Current Pharmaceutical Design Particle-based Vaccines for HIV-1 Infection
Current Drug Targets - Infectious Disorders HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET
Current Drug Targets Does Erythropoietin Always Win?
Current Medicinal Chemistry Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Current Molecular Medicine Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Current Pharmaceutical Design